Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

SundrugLtd

TSE:9989
Snowflake Description

Flawless balance sheet average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9989
TSE
¥393B
Market Cap
  1. Home
  2. JP
  3. Consumer Retailing
Company description

Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
9989 Share Price and Events
7 Day Returns
0%
TSE:9989
1.3%
JP Consumer Retailing
5.1%
JP Market
1 Year Returns
12.9%
TSE:9989
3.6%
JP Consumer Retailing
-10.9%
JP Market
9989 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SundrugLtd (9989) 0% -1.5% -15.8% 12.9% -13.5% 7.7%
JP Consumer Retailing 1.3% 6.1% -6.5% 3.6% 4.3% 5.6%
JP Market 5.1% 1.7% -17.6% -10.9% -3% -7.5%
1 Year Return vs Industry and Market
  • 9989 outperformed the Consumer Retailing industry which returned 3.6% over the past year.
  • 9989 outperformed the Market in Japan which returned -10.9% over the past year.
Price Volatility
9989
Industry
5yr Volatility vs Market

9989 Value

 Is SundrugLtd undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of SundrugLtd to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for SundrugLtd.

TSE:9989 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5%
Perpetual Growth Rate 10-Year JP Government Bond Rate -0.1%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for TSE:9989
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year JP Govt Bond Rate -0.1%
Equity Risk Premium S&P Global 6.3%
Consumer Retailing Unlevered Beta Simply Wall St/ S&P Global 0.39
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.393 (1 + (1- 30.86%) (0%))
0.594
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.09% + (0.8 * 6.33%)
4.97%

Discounted Cash Flow Calculation for TSE:9989 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for SundrugLtd is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

TSE:9989 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 4.97%)
2020 19,987.00 Analyst x3 19,039.95
2021 17,749.67 Analyst x6 16,107.45
2022 18,561.67 Analyst x6 16,046.18
2023 18,602.00 Analyst x2 15,319.08
2024 20,134.00 Analyst x2 15,795.06
2025 25,700.00 Analyst x1 19,206.25
2026 27,681.61 Est @ 7.71% 19,706.94
2027 29,168.23 Est @ 5.37% 19,781.35
2028 30,256.86 Est @ 3.73% 19,547.36
2029 31,039.18 Est @ 2.59% 19,102.61
Present value of next 10 years cash flows ¥179,652.00
TSE:9989 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ¥31,039.18 × (1 + -0.09%) ÷ (4.97% – -0.09%)
¥612,386.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥612,386.39 ÷ (1 + 4.97%)10
¥376,884.32
TSE:9989 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥179,652.00 + ¥376,884.32
¥556,536.32
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥556,536.32 / 116.90
¥4760.79
TSE:9989 Discount to Share Price
Calculation Result
Value per share (JPY) From above. ¥4,760.79
Current discount Discount to share price of ¥3,365.00
= -1 x (¥3,365.00 - ¥4,760.79) / ¥4,760.79
29.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price SundrugLtd is available for.
Intrinsic value
29%
Share price is ¥3365 vs Future cash flow value of ¥4760.79
Current Discount Checks
For SundrugLtd to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • SundrugLtd's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • SundrugLtd's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SundrugLtd's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SundrugLtd's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSE:9989 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in JPY ¥210.13
TSE:9989 Share Price ** TSE (2020-04-09) in JPY ¥3365
Japan Consumer Retailing Industry PE Ratio Median Figure of 84 Publicly-Listed Consumer Retailing Companies 16.3x
Japan Market PE Ratio Median Figure of 3,072 Publicly-Listed Companies 12.4x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SundrugLtd.

TSE:9989 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:9989 Share Price ÷ EPS (both in JPY)

= 3365 ÷ 210.13

16.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SundrugLtd is good value based on earnings compared to the JP Consumer Retailing industry average.
  • SundrugLtd is overvalued based on earnings compared to the Japan market.
Price based on expected Growth
Does SundrugLtd's expected growth come at a high price?
Raw Data
TSE:9989 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.01x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
3.1%per year
Japan Consumer Retailing Industry PEG Ratio Median Figure of 35 Publicly-Listed Consumer Retailing Companies 2.24x
Japan Market PEG Ratio Median Figure of 1,281 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

TSE:9989 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.01x ÷ 3.1%

5.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SundrugLtd is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on SundrugLtd's assets?
Raw Data
TSE:9989 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in JPY ¥1,558.51
TSE:9989 Share Price * TSE (2020-04-09) in JPY ¥3365
Japan Consumer Retailing Industry PB Ratio Median Figure of 97 Publicly-Listed Consumer Retailing Companies 1.04x
Japan Market PB Ratio Median Figure of 3,578 Publicly-Listed Companies 0.86x
TSE:9989 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:9989 Share Price ÷ Book Value per Share (both in JPY)

= 3365 ÷ 1,558.51

2.16x

* Primary Listing of SundrugLtd.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SundrugLtd is overvalued based on assets compared to the JP Consumer Retailing industry average.
X
Value checks
We assess SundrugLtd's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Consumer Retailing industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Consumer Retailing industry average (and greater than 0)? (1 check)
  5. SundrugLtd has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

9989 Future Performance

 How is SundrugLtd expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
3.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SundrugLtd expected to grow at an attractive rate?
  • SundrugLtd's earnings growth is expected to exceed the low risk savings rate of -0.1%.
Growth vs Market Checks
  • SundrugLtd's earnings growth is positive but not above the Japan market average.
  • SundrugLtd's revenue growth is expected to exceed the Japan market average.
Annual Growth Rates Comparison
Raw Data
TSE:9989 Future Growth Rates Data Sources
Data Point Source Value (per year)
TSE:9989 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 3.1%
TSE:9989 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 3.7%
Japan Consumer Retailing Industry Earnings Growth Rate Market Cap Weighted Average 8.3%
Japan Consumer Retailing Industry Revenue Growth Rate Market Cap Weighted Average 3.4%
Japan Market Earnings Growth Rate Market Cap Weighted Average 9.3%
Japan Market Revenue Growth Rate Market Cap Weighted Average 3.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSE:9989 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSE:9989 Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2025-03-31
2024-03-31 704,000 31,200 27,900 1
2023-03-31 680,000 30,600 27,300 1
2022-03-31 667,717 34,822 27,167 6
2021-03-31 639,350 33,703 26,250 6
2020-04-09
2020-03-31 612,983 36,966 25,117 6
TSE:9989 Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-12-31 607,565 24,564
2019-09-30 612,185 37,134 25,742
2019-06-30 594,960 24,342
2019-03-31 588,069 31,091 23,933
2018-12-31 583,085 24,288
2018-09-30 578,241 32,112 24,554
2018-06-30 571,724 24,948
2018-03-31 564,215 36,148 24,829
2017-12-31 555,031 24,590
2017-09-30 546,370 35,375 24,155
2017-06-30 536,737 23,684
2017-03-31 528,394 28,226 23,312

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • SundrugLtd's earnings are expected to grow by 3.1% yearly, however this is not considered high growth (20% yearly).
  • SundrugLtd's revenue is expected to grow by 3.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSE:9989 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from SundrugLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSE:9989 Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2025-03-31
2024-03-31 238.70 238.70 238.70 1.00
2023-03-31 233.50 233.50 233.50 1.00
2022-03-31 232.39 238.70 228.40 6.00
2021-03-31 224.57 228.40 223.27 6.00
2020-04-09
2020-03-31 214.86 219.00 211.30 6.00
TSE:9989 Past Financials Data
Date (Data in JPY Millions) EPS *
2019-12-31 210.13
2019-09-30 220.21
2019-06-30 208.25
2019-03-31 204.75
2018-12-31 207.79
2018-09-30 210.07
2018-06-30 213.44
2018-03-31 212.31
2017-12-31 210.25
2017-09-30 206.54
2017-06-30 202.06
2017-03-31 197.32

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • SundrugLtd is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess SundrugLtd's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Japan market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Japan market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SundrugLtd has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

9989 Past Performance

  How has SundrugLtd performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SundrugLtd's growth in the last year to its industry (Consumer Retailing).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SundrugLtd's year on year earnings growth rate has been positive over the past 5 years.
  • SundrugLtd's 1-year earnings growth is less than its 5-year average (1.1% vs 7.3%)
  • SundrugLtd's earnings growth has exceeded the JP Consumer Retailing industry average in the past year (1.1% vs 0.2%).
Earnings and Revenue History
SundrugLtd's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SundrugLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSE:9989 Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 607,565.00 24,564.00 116,270.00
2019-09-30 612,185.00 25,742.00 115,241.00
2019-06-30 594,960.00 24,342.00 113,283.00
2019-03-31 588,069.00 23,933.00 111,671.00
2018-12-31 583,085.00 24,288.00 110,398.00
2018-09-30 578,241.00 24,554.00 108,759.00
2018-06-30 571,724.00 24,948.00 106,650.00
2018-03-31 564,215.00 24,829.00 104,620.00
2017-12-31 555,031.00 24,590.00 102,601.00
2017-09-30 546,370.00 24,155.00 100,582.00
2017-06-30 536,737.00 23,684.00 98,425.00
2017-03-31 528,394.00 23,312.00 96,507.00
2016-12-31 524,155.00 22,684.00 95,348.00
2016-09-30 517,289.00 22,216.00 93,739.00
2016-06-30 511,786.00 22,207.00 92,456.00
2016-03-31 503,773.00 21,569.00 90,867.00
2015-12-31 492,036.00 20,881.00 88,687.00
2015-09-30 480,933.00 19,971.00 86,985.00
2015-06-30 466,704.00 18,056.00 84,714.00
2015-03-31 445,818.00 16,362.00 82,168.00
2014-12-31 449,548.00 15,122.00 80,870.00
2014-09-30 442,504.00 14,389.00 78,936.00
2014-06-30 440,575.00 15,167.00 77,781.00
2014-03-31 447,819.00 15,754.00 77,500.00
2013-12-31 431,272.00 16,335.00 75,547.00
2013-09-30 425,005.00 16,001.00 74,386.00
2013-06-30 417,622.00 15,581.00 73,018.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • SundrugLtd has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • SundrugLtd used its assets more efficiently than the JP Consumer Retailing industry average last year based on Return on Assets.
  • SundrugLtd's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess SundrugLtd's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Consumer Retailing industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SundrugLtd has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

9989 Health

 How is SundrugLtd's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SundrugLtd's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SundrugLtd is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SundrugLtd's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SundrugLtd's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • SundrugLtd has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SundrugLtd Company Filings, last reported 3 months ago.

TSE:9989 Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 182,190.00 0.00 74,386.00
2019-09-30 180,685.00 0.00 82,864.00
2019-06-30 173,726.00 0.00 72,117.00
2019-03-31 171,056.00 0.00 70,239.00
2018-12-31 165,484.00 0.00 66,121.00
2018-09-30 162,748.00 0.00 65,194.00
2018-06-30 157,139.00 0.00 59,620.00
2018-03-31 154,828.00 0.00 60,487.00
2017-12-31 148,896.00 0.00 57,455.00
2017-09-30 145,121.00 0.00 54,981.00
2017-06-30 139,107.00 0.00 46,896.00
2017-03-31 136,335.00 0.00 45,957.00
2016-12-31 130,678.00 0.00 46,289.00
2016-09-30 126,798.00 0.00 41,421.00
2016-06-30 136,206.00 0.00 52,680.00
2016-03-31 133,285.00 0.00 52,496.00
2015-12-31 128,332.00 0.00 50,725.00
2015-09-30 124,733.00 0.00 44,372.00
2015-06-30 119,246.00 0.00 39,842.00
2015-03-31 115,987.00 0.00 34,640.00
2014-12-31 111,589.00 90.00 33,712.00
2014-09-30 108,293.00 2,052.00 29,861.00
2014-06-30 114,692.00 451.00 36,051.00
2014-03-31 113,204.00 630.00 47,423.00
2013-12-31 110,146.00 809.00 39,503.00
2013-09-30 107,408.00 989.00 32,770.00
2013-06-30 103,033.00 1,186.00 29,943.00
  • SundrugLtd has no debt.
  • SundrugLtd has no debt compared to 5 years ago when it was 0.1%.
  • SundrugLtd has no debt, it does not need to be covered by operating cash flow.
  • SundrugLtd has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess SundrugLtd's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SundrugLtd has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

9989 Dividends

 What is SundrugLtd's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.02%
Current annual income from SundrugLtd dividends. Estimated to be 2.22% next year.
If you bought ¥2,000 of SundrugLtd shares you are expected to receive ¥40 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • SundrugLtd's pays a higher dividend yield than the bottom 25% of dividend payers in Japan (1.7%).
  • SundrugLtd's dividend is below the markets top 25% of dividend payers in Japan (3.92%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSE:9989 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Japan Consumer Retailing Industry Average Dividend Yield Market Cap Weighted Average of 93 Stocks 1.8%
Japan Market Average Dividend Yield Market Cap Weighted Average of 2987 Stocks 2.8%
Japan Minimum Threshold Dividend Yield 10th Percentile 1%
Japan Bottom 25% Dividend Yield 25th Percentile 1.7%
Japan Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSE:9989 Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2025-03-31
2024-03-31 86.00 1.00
2023-03-31 82.00 1.00
2022-03-31 75.00 6.00
2021-03-31 71.50 6.00
2020-04-09
2020-03-31 68.67 6.00
TSE:9989 Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-11-14 68.000 1.863
2019-11-08 68.000 1.770
2019-08-09 68.000 2.020
2019-06-24 68.000 2.280
2019-05-10 68.000 2.424
2018-11-09 66.000 1.955
2018-06-25 66.000 1.593
2018-05-11 66.000 1.306
2018-02-14 54.000 1.059
2018-02-09 54.000 1.148
2017-11-09 54.000 1.074
2017-08-09 54.000 1.154
2017-05-11 54.000 1.280
2017-02-14 45.000 1.177
2017-02-09 45.000 1.179
2016-11-14 45.000 1.142
2016-11-10 45.000 1.231
2016-06-27 45.000 1.074
2016-05-12 45.000 0.990
2016-02-12 40.000 1.000
2016-02-10 40.000 1.121
2015-11-13 40.000 1.044
2015-11-09 40.000 1.093
2015-06-22 35.000 1.032
2015-05-15 35.000 1.070
2015-02-13 30.000 0.985
2015-02-09 30.000 1.075
2014-11-13 30.000 1.221
2014-11-10 30.000 1.214
2014-06-23 30.000 1.271
2014-05-15 30.000 1.312
2014-02-13 26.000 1.227
2014-02-10 26.000 1.264
2013-11-13 26.000 1.134
2013-11-11 26.000 1.095
2013-06-24 26.000 1.143
2013-05-15 26.000 1.304
2013-02-14 22.000 1.104
2013-02-08 22.000 1.198
2012-11-13 22.000 1.426
2012-11-09 22.000 1.520
2012-08-10 22.000 1.555
2012-06-25 22.000 1.646
2012-05-15 22.000 1.806
2012-02-14 18.000 1.482
2012-02-10 18.000 1.582
2011-11-14 18.000 1.546
2011-11-10 18.000 1.539
2011-08-10 18.000 1.496
2011-06-27 18.000 1.444
2011-05-13 18.000 1.507
2011-02-14 16.000 1.387
2011-02-10 16.000 1.262
2010-11-12 16.000 1.366
2010-11-10 16.000 1.433
2010-08-10 16.000 1.434
2010-06-28 16.000 1.438
2010-05-14 16.000 1.475
2010-02-12 15.000 1.375
2010-02-09 15.000 1.423
2009-11-13 15.000 1.402
2009-11-09 15.000 1.392
2009-06-29 15.000 1.358

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of SundrugLtd's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.1x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SundrugLtd's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SundrugLtd afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SundrugLtd has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

9989 Management

 What is the CEO of SundrugLtd's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Akao Kimiya
AGE 54
TENURE AS CEO 6.7 years
CEO Bio

Mr. Akao Kimiya has been the President of Sundrug Co., Ltd since August 2013 and serves as its General Manager of Business Administration. Mr. Kimiya served as the General Manager of Administrative Division at Sundrug Co., Ltd. since October 2005. He joined Sundrug Co., Ltd. in March 1984 and served as Section Chief Products Division since April 1995; Vice Chief Products Division since April 2000; General Manager, Administrative Division since June 2001. He has been a Representative Director of Sundrug Co., Ltd. since June 2002.

CEO Compensation
  • Insufficient data for Akao to compare compensation growth.
  • Insufficient data for Akao to establish whether their remuneration is reasonable compared to companies of similar size in Japan.
Management Team Tenure

Average tenure and age of the SundrugLtd management team in years:

6.7
Average Tenure
54
Average Age
  • The average tenure for the SundrugLtd management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Akao Kimiya

TITLE
President
AGE
54
TENURE
6.7 yrs

Tsuruta Kazuhiro

TITLE
Chief of Office of President
AGE
54
TENURE
6.7 yrs

Sakai Yoshimitsu

TITLE
Manager of Store Development Department & Director
AGE
55
TENURE
15 yrs
Board of Directors Tenure

Average tenure and age of the SundrugLtd board of directors in years:

9.8
Average Tenure
54.5
Average Age
  • The tenure for the SundrugLtd board of directors is about average.
Board of Directors

Saitsu Tatsuro

TITLE
Chairman of the Board
COMPENSATION
¥118M
AGE
71
TENURE
6.7 yrs

Akao Kimiya

TITLE
President
AGE
54
TENURE
17.8 yrs

Tsuruta Kazuhiro

TITLE
Chief of Office of President
AGE
54
TENURE
19.8 yrs

Sakai Yoshimitsu

TITLE
Manager of Store Development Department & Director
AGE
55
TENURE
9.8 yrs

Tada Naoki

TITLE
Director
AGE
57
TENURE
18.8 yrs

Sadakata Hiroshi

TITLE
Director
AGE
49
TENURE
11.8 yrs

Nobuhiko Sugiura

TITLE
External Director
AGE
53
TENURE
5.8 yrs

Kenji Fujiwara

TITLE
External Director
AGE
73
TENURE
4.8 yrs

Takashi Tada

TITLE
Director
AGE
50

Ozawa Tetsuro

TITLE
External Auditor
AGE
61
TENURE
7.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (¥) Value (¥)
X
Management checks
We assess SundrugLtd's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SundrugLtd has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

9989 News

Simply Wall St News

9989 Company Info

Description

Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offers food, cosmetics, home appliances, clothing, car supplies, sports and leisure products, liquors, and pharmaceutical products. The company was founded in 1957 and is headquartered in Fuchu, Japan.

Details
Name: Sundrug Co.,Ltd.
9989
Exchange: TSE
Founded: 1957
¥393,368,607,680
116,900,032
Website: http://www.sundrug.co.jp
Address: Sundrug Co.,Ltd.
1 in 38, Wakamatsucho,
Fuchu,
Tokyo, 183-0005,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 9989 Common Shares The Tokyo Stock Exchange JP JPY 24. Aug 1994
OTCPK SDGC.F Common Shares Pink Sheets LLC US USD 24. Aug 1994
Number of employees
Current staff
Staff numbers
4,984
SundrugLtd employees.
Industry
Drug Retail
Consumer Retailing
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 15:42
End of day share price update: 2020/04/09 00:00
Last estimates confirmation: 2020/02/14
Last earnings filing: 2020/02/14
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.